Figure 2
Figure 2. Survival analysis of LRF CLL4 cases accounting for NOTCH1, SF3B1 and TP53 gene status. (A-B) Overall survival for NOTCH1 and SF3B1 mutational status, respectively. (C-D) Overall survival and progression free survival, respectively. Patient subgroups with mutations in NOTCH1 (but wild-type for SF3B1 and TP53), SF3B1 (but wild-type for NOTCH1 and TP53), and TP53 del/mut cases (but wild-type for SF3B1 and NOTCH1); highlighted by a solid black, dashed black, and dashed gray line, respectively. The solid-gray line identifies the WT subgroup that is wild-type for NOTCH1, SF3B1, and TP53 (that lack either a deletion or mutation). The P values are derived from Kaplan-Meier analysis with a log-rank test and median survival times with 95% confidence intervals.

Survival analysis of LRF CLL4 cases accounting for NOTCH1, SF3B1 and TP53 gene status. (A-B) Overall survival for NOTCH1 and SF3B1 mutational status, respectively. (C-D) Overall survival and progression free survival, respectively. Patient subgroups with mutations in NOTCH1 (but wild-type for SF3B1 and TP53), SF3B1 (but wild-type for NOTCH1 and TP53), and TP53 del/mut cases (but wild-type for SF3B1 and NOTCH1); highlighted by a solid black, dashed black, and dashed gray line, respectively. The solid-gray line identifies the WT subgroup that is wild-type for NOTCH1, SF3B1, and TP53 (that lack either a deletion or mutation). The P values are derived from Kaplan-Meier analysis with a log-rank test and median survival times with 95% confidence intervals.

Close Modal

or Create an Account

Close Modal
Close Modal